Form 4 for BRTX BioRestorative Therapies, Inc.
Accepted 2023-02-02 00:00:00 ET · period of report 2023-02-01 · accession 0001567619-23-001697 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-02 | 2023-02-01 | BRTX | ALSTODT LANCE | Pres, CEO, COB, Dir | P - Purchase | $3.10 | +400 | 187.3K | +0.2% | +$1,240 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-01 | P | A | 400 | $3.10 | 187,321 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $3.07 to $3.12 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. (F2) Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. |